Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Dec;74(12):2018–2023. doi: 10.1038/bjc.1996.670

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

S H Goey 1, J W Gratama 1, J N Primrose 1, U Ward 1, R H Mertelsmann 1, B Osterwalder 1, J Verweij 1, G Stoter 1
PMCID: PMC2074801  PMID: 8980407

Abstract

Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer. This phase II study was designed to evaluate the anti-tumour activity and toxicity of the combination of IL-2, IFN alpha-2a and 5-FU in patients with advanced colorectal cancer. Forty-four patients with metastatic colorectal cancer were treated, predominantly on an outpatient basis, with subcutaneous IFN alpha-2a and IL-2 three times per week followed by once a week bolus intravenous 5-FU injections. There were six (14%) partial responses among the 43 evaluable patients [95% confidence interval (CI) 5-28%]. Twenty-four patients had stable disease (56%) and 13 patients (30%) showed progressive disease. The median time to progressive disease in 43 patients was 19 weeks (range 2-72 weeks) and in responders 34 weeks (range 24-30 weeks). The median overall survival was 47 weeks (range 2-85 weeks) and in responders 60 weeks (range 35-71 weeks). Treatment-related toxic effects included fatigue, nausea and vomiting. Granulocytopenia was the main reason for the dose reductions or treatment interruptions in 32 out of 44 patients. One patient died of toxicity due to renal failure. Serial assessments of immunophenotyping and cytolytic activities of peripheral blood lymphocytes did not show changes in the numbers of circulating natural killer (NK) cells or in the levels of NK and lymphokine-activated killer (LAK) cytolytic activities. This regimen of IL-2 and IFN alpha-2a with 5-FU has only modest anti-tumour activity in advanced colorectal cancer.

Full text

PDF
2018

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Kirchner H., Hänninen E. L., Menzel T., Deckert M., Franzke A., Schomburg A., Poliwoda H. Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon. Oncology. 1994 May-Jun;51(3):273–275. doi: 10.1159/000227348. [DOI] [PubMed] [Google Scholar]
  2. Cameron R. B., McIntosh J. K., Rosenberg S. A. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res. 1988 Oct 15;48(20):5810–5817. [PubMed] [Google Scholar]
  3. Cascinu S., Del Ferro E., Fedeli A., Grianti C., Foglietti G., Olivieri Q., Acetoso M., Bartolucci M., Saba V., Lungarotti F. Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. Cancer Res. 1993 Nov 15;53(22):5429–5432. [PubMed] [Google Scholar]
  4. Chikkala N. F., Lewis I., Ulchaker J., Stanley J., Tubbs R., Finke J. H. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Cancer Res. 1990 Feb 15;50(4):1176–1182. [PubMed] [Google Scholar]
  5. Elias L., Crissman H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res. 1988 Sep 1;48(17):4868–4873. [PubMed] [Google Scholar]
  6. Feldman M., Eisenbach L. MHC class I genes controlling the metastatic phenotype of tumor cells. Semin Cancer Biol. 1991 Oct;2(5):337–346. [PubMed] [Google Scholar]
  7. Gratama J. W., Bruin R. J., Lamers C. H., Oosterom R., Braakman E., Stoter G., Bolhuis R. L. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2. Clin Exp Immunol. 1993 May;92(2):185–193. doi: 10.1111/j.1365-2249.1993.tb03378.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gratama J. W., Schmitz P. I., Goey S. H., Lamers C. H., Stoter G., Bolhuis R. L. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes). Int J Cancer. 1996 Jan 17;65(2):152–160. doi: 10.1002/(SICI)1097-0215(19960117)65:2<152::AID-IJC5>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  9. Gresser I. Antitumor effects of interferon. Acta Oncol. 1989;28(3):347–353. doi: 10.3109/02841868909111205. [DOI] [PubMed] [Google Scholar]
  10. HEIDELBERGER C., CHAUDHURI N. K., DANNEBERG P., MOOREN D., GRIESBACH L., DUSCHINSKY R., SCHNITZER R. J., PLEVEN E., SCHEINER J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957 Mar 30;179(4561):663–666. doi: 10.1038/179663a0. [DOI] [PubMed] [Google Scholar]
  11. Heys S. D., Eremin O., Ruggeri E. M., Pein F., Rainer H., Oskam R., de Peuter R. A., Palmer P. A., Franks C. R. A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer. 1995;31A(1):19–25. doi: 10.1016/0959-8049(94)00360-h. [DOI] [PubMed] [Google Scholar]
  12. Hill M., Norman A., Cunningham D., Findlay M., Nicolson V., Hill A., Iveson A., Evans C., Joffe J., Nicolson M. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995 Jun;13(6):1297–1302. doi: 10.1200/JCO.1995.13.6.1297. [DOI] [PubMed] [Google Scholar]
  13. Hill M., Norman A., Cunningham D., Findlay M., Watson M., Nicolson V., Webb A., Middleton G., Ahmed F., Hickish T. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 1995 Sep;13(9):2317–2323. doi: 10.1200/JCO.1995.13.9.2317. [DOI] [PubMed] [Google Scholar]
  14. Kemeny N., Younes A., Seiter K., Kelsen D., Sammarco P., Adams L., Derby S., Murray P., Houston C. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer. 1990 Dec 15;66(12):2470–2475. doi: 10.1002/1097-0142(19901215)66:12<2470::aid-cncr2820661205>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  15. Köhne C. H., Wilke H., Hecker H., Schöffski P., Käufer C., Rauschecker H., Andreesen R., Ohl U., Lange H. J., Klaassen U. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). Ann Oncol. 1995 May;6(5):461–466. doi: 10.1093/oxfordjournals.annonc.a059216. [DOI] [PubMed] [Google Scholar]
  16. Marincola F. M., White D. E., Wise A. P., Rosenberg S. A. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol. 1995 May;13(5):1110–1122. doi: 10.1200/JCO.1995.13.5.1110. [DOI] [PubMed] [Google Scholar]
  17. Miyoshi T., Ogawa S., Kanamori T., Nobuhara M., Namba M. Interferon potentiates cytotoxic effects of 5-fluorouracil on cell proliferation of established human cell lines originating from neoplastic tissues. Cancer Lett. 1983 Jan;17(3):239–247. doi: 10.1016/0304-3835(83)90160-x. [DOI] [PubMed] [Google Scholar]
  18. Moertel C. G. Chemotherapy for colorectal cancer. N Engl J Med. 1994 Apr 21;330(16):1136–1142. doi: 10.1056/NEJM199404213301608. [DOI] [PubMed] [Google Scholar]
  19. Onodera H., Somers S. S., Guillou P. J. Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer. 1990 Dec;62(6):1042–1046. doi: 10.1038/bjc.1990.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pazdur R., Ajani J. A., Patt Y. Z., Winn R., Jackson D., Shepard B., DuBrow R., Campos L., Quaraishi M., Faintuch J. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol. 1990 Dec;8(12):2027–2031. doi: 10.1200/JCO.1990.8.12.2027. [DOI] [PubMed] [Google Scholar]
  21. Ridolfi R., Maltoni R., Riccobon A., Flamini E., Fedriga R., Milandri C., Pezzi L., Velotti F., Santoni A., Amadori D. A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. J Chemother. 1994 Aug;6(4):265–271. doi: 10.1080/1120009x.1994.11741163. [DOI] [PubMed] [Google Scholar]
  22. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  23. Smith M. E., Bodmer W. F., Bodmer J. G. Selective loss of HLA-A,B,C locus products in colorectal adenocarcinoma. Lancet. 1988 Apr 9;1(8589):823–824. doi: 10.1016/s0140-6736(88)91682-0. [DOI] [PubMed] [Google Scholar]
  24. Wadler S., Schwartz E. L., Goldman M., Lyver A., Rader M., Zimmerman M., Itri L., Weinberg V., Wiernik P. H. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1989 Dec;7(12):1769–1775. doi: 10.1200/JCO.1989.7.12.1769. [DOI] [PubMed] [Google Scholar]
  25. Weber J. S., Rosenberg S. A. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988 Oct 15;48(20):5818–5824. [PubMed] [Google Scholar]
  26. Yang J. C., Shlasko E., Ritchey J. L., Landry J. G., White D. E., Rosenberg S. A. Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. Eur J Cancer. 1993;29A(3):355–359. doi: 10.1016/0959-8049(93)90385-s. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES